LGMD R1 is a problematic disease in the field of the nervous system, with clinical performance being complex and often involving multi-system congestion. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of LGMD requires a comprehensive assessment platform including clinical performance, imaging, laboratory testing and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment. Individualised development of treatment plans for treatment and management of LGMD R1 typically includes drug treatment, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many neurological diseases that have been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of LGMD R1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.